REMSleep Holdings Reports No Revenue in Q1 2025, Narrows Losses Amid Transition to DeltaWave Product

REMSleep Holdings Inc. has reported its financial results for the first quarter of 2025, revealing a significant shift in its revenue generation and overall financial health. The company did not recognize any revenue during the three months ended March 31, 2025, a stark contrast to the $57,881 in revenue reported for the same period in 2024. This decline is attributed to the company's decision to cease sales of its CPAP machines as it prepares to launch its new DeltaWave product, which received FDA 510(k) approval in July 2024.

In terms of expenses, REMSleep's total operating expenses decreased to $131,315 in Q1 2025 from $168,506 in Q1 2024, marking a reduction of approximately 22%. This decrease was driven by lower general and administrative expenses, which fell by 36.3% to $52,424, primarily due to reduced investor relations and consulting costs. Despite these reductions, the company reported a net loss of $85,488 for the quarter, an improvement from the net loss of $252,580 in the prior year, indicating a narrowing of losses as the company transitions its business model.

Operationally, REMSleep's total assets increased to $604,723 as of March 31, 2025, up from $591,697 at the end of 2024. The company’s cash position improved slightly, with cash at the end of the quarter reported at $507,247 compared to $463,343 at the end of the previous year. However, total liabilities also rose significantly, from $254,994 to $353,508, largely due to an increase in convertible notes payable. The company’s accumulated deficit has now reached $15,356,244, raising concerns about its ability to continue as a going concern without additional financing.

As of March 31, 2025, REMSleep had 1,535,389,060 shares of common stock outstanding, reflecting an increase from 1,523,620,126 shares at the end of 2024. The company continues to explore financing options to support its operations and product development. Management has indicated that the successful commercialization of the DeltaWave product is critical for future revenue generation and overall business viability. The company aims to capture a 10% market share in the sleep apnea product segment within the next 24 months, contingent upon adequate funding and successful product launch.

Looking ahead, REMSleep Holdings Inc. faces substantial challenges, including the need to secure additional capital and effectively market its new product. The management's plans include obtaining funding from new investors and implementing strategies to generate sales. However, the company acknowledges that the outcome of these efforts remains uncertain, and its financial statements do not reflect any adjustments that may arise from these risks.